| Drugs by Condition |  |
Angioedema Medications
Definition of Angioedema: Angioedema is the development of large welts below the surface of the skin, especially around the eyes and lips. The welts may also affect the hands, feet, and throat. The condition can be associated with allergies and histamine release.
Drugs associated with Angioedema
The following drugs and medications are in some way related to, or used in the treatment of Angioedema. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
Drug Name  ( View by: Brand | Generic )
|
Reviews | Ratings |
||
|---|---|---|---|---|
Winstrol (More...) generic name: stanozolol class: androgens and anabolic steroids | 0 review(s) | Not rated - Be the first | ||
| Danocrine (Pro, More...)generic name: danazol class: miscellaneous hormones | 0 review(s) | Not rated - Be the first | ||
See also...
Angioedema Medications in the Pipeline
- June 23, 2008 - Jerini to Submit Complete Response to the FDA for Icatibant in the Treatment of HAE
- April 24, 2008 - FDA Issues Not Approvable Letter for Icatibant in the Treatment of HAE
- January 8, 2008 - FDA Cancels Advisory Committee Meeting for Icatibant in the Treatment of HAE - Priority Review of Jerini's NDA Continues
- December 21, 2007 - Jerini Receives NDA Filing Acceptance and Priority Review from the FDA for Icatibant in the Treatment of HAE
- October 31, 2007 - Jerini Submits New Drug Application for Icatibant in the Treatment of HAE to the FDA and Requests Priority Review
- October 8, 2007 - Jerini Initiates FDA Submission Process of New Drug Application for Icatibant in the Treatment of HAE
- January 29, 2008 - Pharming Provides Update on Rhucin
- June 8, 2009 - Dyax Announces FDA Accepts for Review the Complete Response Submission for DX-88 in Hereditary Angioedema
- March 27, 2009 - Dyax Receives Complete Response Letter from FDA for DX-88 in Acute Attacks of Hereditary Angioedema
- February 5, 2009 - FDA Advisory Committee Favors Approval of DX-88 for Acute Attacks of Hereditary Angioedema
- January 13, 2009 - Dyax Announces FDA Advisory Committee to Review DX-88 for Hereditary Angioedema
- November 21, 2008 - FDA Accepts Filing and Grants Priority Review for DX-88 for Hereditary Angioedema
- September 24, 2008 - Dyax Announces Completion of Biologics License Application for DX-88 for Hereditary Angioedema
Latest Angioedema Blog Post
C1-Esterase Inhibitor Concentrate Rapidly Relieves Acute Swelling Attacks Across All Body Sites in Patients with Hereditary Angioedema, According to Study
Additional data presented at the 2009 AAAAI Annual Meeting shows that C1-INH improves health-related quality of life measures in patients with HAE
WASHINGTON, March 15 /PRNewswire/ -- C1-esterase inhibitor (C1-INH) concentrate is an effective, well-tolerated...
View all Angioedema blog posts.
Angioedema Support Group Questions
Go to the Angioedema support group or view all Angioedema questions.
Ask a Question about Angioedema:
Learn more about Angioedema
Medical encyclopedia results for:
